Brief: Therapeutic Solutions International Reports Its Nanostilbene Nutraceutical Product Enhances Efficacy Of Cancer Immunotherapy In Animal Model Of Cancer
22/07/2019 14:06
July 22 (Reuters) - Therapeutic Solutions International Inc
TSOI.PK :
* THERAPEUTIC SOLUTIONS INTERNATIONAL REPORTS ITS
NANOSTILBENE™
NUTRACEUTICAL PRODUCT ENHANCES EFFICACY OF FDA CLEARED CANCER
IMMUNOTHERAPY IN ANIMAL MODEL OF CANCER
Source text for Eikon: ID:nGNX5tvH6X
Further company coverage: TSOI.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Therapeutic Solutions International
See all newsBrief: Therapeutic Solutions International Files For Orphan Drug Designation Use Of Jadicell Adult Stem Cells
Brief: Therapeutic Solutions International Files To Initiate Phase Iii Clinical Trial For Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive Covid-19 Data With Jadicell Stem Cell Therapy
Brief: Therapeutic Solutions International Files With FDA To Expand Ongoing Phase III Clinical Trial To Include All Causes Of Acute Respiratory Distress Syndrome
Brief: Therapeutic Solutions Granted Emergency IND By FDA For Stem Cell Therapy
Brief: Therapeutic Solutions International Completes Purchase Of FDA Phase Iii Jadicell Stem Cell Investigational New Drug Application From University Of Miami